ArticleDiscover oncology2026
Long-term outcomes of rare pure histological subtypes of breast cancer in a tertiary single-center retrospective cohort.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRare pure histological breast cancer subtypes represent a clinically heterogeneous group of tumors with diverse biological behaviours and prognostic profiles. Due to their rarity, data, particularly regarding long-term survival outcomes, are limited and controversial. This study aimed to evaluate the clinicopathological features and long-term survival outcomes of patients diagnosed with rare pure histological breast cancer subtypes in a single tertiary center.
methodsThis retrospective single-center study included 117 patients diagnosed with pure rare breast cancer histologies between November 2000 and February 2024. These included mucinous, metaplastic, micropapillary, and tubular carcinomas, as well as malignant phyllodes tumors. Clinicopathological features, treatment methods, recurrence risks, and survival outcomes were analyzed. 5-year and 10-year overall survival (OS) rates were calculated.
resultsThe most common subtype was mucinous carcinoma (41.9%), followed by metaplastic (25.6%), micropapillary (14.5%), tubular carcinoma (10.2%), and malignant phyllodes tumor (7.7%). Favourable biological features such as low grade, low Ki-67 proliferation index, and high hormone receptor expression were dominant in mucinous and tubular carcinomas, while metaplastic and micropapillary carcinomas frequently exhibited aggressive biological features such as high grade, high Ki-67, and more frequent lymph node involvement. In long-term follow-up, recurrence was most common in malignant phyllodes tumors, micropapillary carcinomas, and metaplastic carcinomas. Five- and ten-year overall survival rates differed significantly among subtypes, with the most favourable outcomes observed in tubular and mucinous carcinomas and relatively lower long-term survival observed in metaplastic and malignant phyllodes tumors.
conclusionsPure rare histological breast cancer subtypes appear to show heterogeneity in clinicopathological features and long-term survival outcomes. Due to the small number of patients in individual subgroups, these findings should be interpreted with caution. Our descriptive data suggest a potential prognostic role for histological subtype and highlight the importance of accurate pathological classification. Long-term follow-up data from tertiary care centers may provide useful descriptive information about the natural history and survival patterns of these rare breast cancer subtypes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.